Clinical Trial Update: Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2 study evaluating whether the compound GSK239512 can promote remyelination in people with relapsing-remitting multi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GSK239512 (GSK239512)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 2 | Status: COMPLETED